Exenatide Extended-Release Injection (Bydureon) (Trays) and Voltaren-XR
Determining the interaction of Exenatide Extended-Release Injection (Bydureon) (Trays) and Voltaren-XR and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Exenatide may rarely cause kidney problems, and combining it with other medications that can also affect the kidney such as diclofenac may increase that risk. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. You should seek immediate medical attention if you develop signs and symptoms that may suggest kidney damage such as nausea, vomiting, loss of appetite, increased or decreased urination, sudden weight gain or weight loss, fluid retention, swelling, shortness of breath, bone pain, muscle cramps, tiredness, weakness, dizziness, confusion, and irregular heart rhythm. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Drugs that affect renal function and/or hydration status may potentiate the adverse renal effects of exenatide. The mechanism of interaction is unknown. Exenatide has not been found to be directly nephrotoxic in preclinical or clinical studies. However, there have been reports of altered renal function, including increased serum creatinine, renal impairment, worsened chronic renal failure, and acute renal failure during postmarketing use. In some cases, hemodialysis or kidney transplantation was required. Some of these events occurred in patients receiving one or more pharmacologic agents known to affect renal function or hydration status (e.g., ACE inhibitors, nonsteroidal anti-inflammatory drugs, diuretics), and some occurred in patients who had been experiencing nausea, vomiting or diarrhea, with or without dehydration. Most cases were reversible with supportive treatment and discontinuation of potentially causative agents, including exenatide.
MANAGEMENT: Clinicians should be aware of the potential for increased adverse renal effects of exenatide during coadministration with drugs that are known to affect renal function or hydration status.
- "Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc, San Diego, CA.
Generic Name: exenatide
Brand name: Byetta Prefilled Pen, Bydureon, Bydureon BCise, Bydureon Pen, Bydureon Tray
Synonyms: Exenatide
Generic Name: diclofenac
Brand name: Cambia, Cataflam, Voltaren-XR, Zipsor, Zorvolex, Voltaren, Dyloject, also Cambia
Synonyms: Voltaren XR
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Exenatide Extended-Release Injection (Bydureon) (Trays)-Von Willebrand Factor
- Exenatide Extended-Release Injection (Bydureon) (Trays)-Von Willebrand factor recombinant
- Exenatide Extended-Release Injection (Bydureon) (Trays)-Von willebrand factor recombinant Intravenous
- Exenatide Extended-Release Injection (Bydureon) (Trays)-Vonvendi
- Exenatide Extended-Release Injection (Bydureon) (Trays)-Vopac
- Exenatide Extended-Release Injection (Bydureon) (Trays)-Vopac MDS
- Voltaren-XR-Exenatide Injection (Byetta)
- Voltaren-XR-Exenatide Subcutaneous
- Voltaren-XR-Exfoliating Moisturizer
- Voltaren-XR-Exforge
- Voltaren-XR-Exforge HCT
- Voltaren-XR-Exjade